There has to be some positive news on the 7th from at least one platform? I thought they had finished the early part of a trials by way of ensuring that the procedure was safe and were now moving it on a pace, which platform was that? My eggs are still in this basket, just hope they're well protected and ready to hatch early 2016!
Thanks monkster. Agreed, hopefully a lead in rns prior to Monday week. I'm really hoping for some good news. REN 003 in particular. Best wishes. Feddie P's I'm still recommending the buy. Wish I could afford to top up further.
Thanks for your enthusiasm and information on this board Freddie. I anticipate a holding RNS soon as someone has been selling. .....equally I hope that someone is taking a position. 2016 is when the early, significant shareholders hoped to see material returns. Not long to wait.
I have copied this snippet straight off Reneuron's Web site. If they are meeting the program, watch this space!
The primary endpoint of the study is safety, with patients being followed up for 12 months post-treatment with monitoring including measurements of visual acuity. Preparations for the study have commenced and we expect the study to begin in the second half of 2015
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.